Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

<div>PET imaging of [68Ga]Ga-DOTA-E(cRGDfK)2 in normal mice at (a) 1 hour and (b) 2 hour after IV injection, 1 h (c) and 2 h (d) blocking using DOTA-E(cRGDfK)2, and PET images of tumor-bearing BALB/c mice at (e) 1 h and (f) 2 h after IV injection of [68Ga]Ga-DOTA-E(cRGDfK)2. White arrows are the indication of the tumor position.</div>

Contrast Media & Molecular Imaging

fig11

Figure 11

Figure 11: Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

Figure 11 | Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer 